[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jacksonville University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100647481","magnesium-supplement-for-sleep-quality-in-women-with-poor-sleep-100647481",false,"NCT07708857","Magnesium Supplement for Sleep Quality in Women With Poor Sleep","Effects of Magnesium Breakthrough on Sleep Quality and Mood in Women With Poor Sleep: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial","Inclusion Criteria:\n\n* Women aged 35-60 U.S.-based, fluent in English Insomnia Severity Index score ≥8 (poor\u002Fsubclinical insomnia) and \\\u003C22 (excluding severe clinical insomnia) No formal sleep disorder diagnosis Consistent bedtime routine (+\u002F-1 hr) Not currently using prescription sleep medications Owns a compatible smartphone (iOS or Android) capable of running the Oura Ring app and study digital platform Willing to wear the Oura Ring throughout the entire study period Nonsmoker Able to provide informed consent and complete all activities\n\nExclusion Criteria:\n\n* Diagnosed sleep disorder Current diagnosis of depression or anxiety disorder Current use of bisphosphonates (e.g., alendronate, risedronate) Shift worker or highly irregular sleep schedule Pregnancy or breastfeeding Known sensitivity to product ingredients Current use of supplements containing more than 25 mg of elemental magnesium Coffee intake greater than 3 cups per day (or equivalent caffeine from other beverages) External or lifestyle factors that may affect sleep patterns (e.g., infant\u002Fchild regularly wakening, excessive noise, snoring partner, pain condition, variable work\u002Fstudy schedule, or mid-to-late afternoon\u002Fevening caffeine intake) BMI ≥32 kg\u002Fm² Current diagnosis of chronic kidney disease or renal impairment, or current use of prescription diuretics Use of melatonin \\>1 mg within 14 days of baseline Recent major life event or acute psychosocial stressor within 30 days of baseline (e.g., bereavement, job loss, separation) that may independently disrupt sleep Participation in other clinical trials in past 30 days\n\nCriteria:\" as headers within a single text field)?",true,"FEMALE","35 Years","60 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will test whether a magnesium supplement (Magnesium Breakthrough) improves sleep quality and mood in women ages 35 to 60 who have poor sleep but no diagnosed sleep disorder. Participants will take the magnesium supplement for two weeks and a matched placebo for two weeks, in random order, separated by a one-week washout period. Neither participants nor study staff will know which product is being taken during each period.\n\nThroughout the study, participants will wear an Oura Ring to track sleep patterns and will complete short daily and biweekly questionnaires about their sleep, mood, stress, and energy levels. The main measure of interest is change in sleep quality, assessed using a validated sleep questionnaire (the Pittsburgh Sleep Quality Index). The study will also look at effects on mood, stress, and objective sleep measures from the Oura Ring.\n\nAll study activities - screening, consent, and data collection - are conducted remotely, so participants can take part from anywhere in the United States.",[28],"Sleep Quality",[30,31,32,33],"magnesium","sleep quality","crossover trial","middle-aged women","NOT_YET_RECRUITING","2026-07-16",{"date":37,"type":38},"2026-07-20","ACTUAL",{"date":40,"type":22},"2026-09",{"date":42,"type":22},"2026-11",{"name":44,"class":45},"Jacksonville University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100588320","effect-of-a-cepham-supplement-on-hot-flashes-and-menopausal-symptoms-in-postmenopausal-women-100588320","NCT06939868","Effect of a Cepham Supplement on Hot Flashes and Menopausal Symptoms in Postmenopausal Women","Effectiveness of 'Cepham Supplement' on Hot Flash Severity\u002FFrequency and Menopausal Symptoms in Postmenopausal Women: A Randomized Double-Blind Placebo-Controlled Trial","Inclusion Criteria:\n\n* Adult women aged 40-60 years.\n* Menopause Rating Scale score: (a) GE 14 and (b) score of 3 or 4 (severe to very severe) for hot flashes (Blumel et al., 2018).\n\nExclusion Criteria:\n\n* Current use of hormone therapy or other medications known to affect hot flashes.\n* Significant comorbidities that may interfere with study participation.","40 Years",{"count":56,"type":22},44,[25],"The goal of this clinical trial is to learn if a daily nutritional supplement can reduce hot flashes and other menopausal symptoms in postmenopausal women.\n\nThe main questions this study aims to answer are:\n\nDoes the supplement reduce the number and severity of daily hot flashes?\n\nDoes it improve other common menopausal symptoms?\n\nResearchers will compare the supplement to a placebo (a look-alike capsule with no active ingredients) to see if it helps manage symptoms during menopause.\n\nParticipants will:\n\nTake either the supplement or a placebo daily for 30 days\n\nTrack their hot flashes each day using a short online survey\n\nComplete a symptom questionnaire at the beginning and end of the study\n\nThis study is for women ages 40-60 who have been postmenopausal for at least one year and currently experience bothersome hot flashes.",[60],"D008593",[62,63,64],"menopause","hot flashes","supplement","2025-04-18",{"date":67,"type":38},"2025-04-23",{"date":69,"type":22},"2025-05-01",{"date":71,"type":22},"2025-09-30",{"name":44,"class":45},""]